Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Approved

EmyriaASX: EMD

2 Drug Candidates

Australian clinical-stage biotech pioneering psychedelic-assisted therapies. In 2025, Emyria became the first company in the world to commercially deliver MDMA-assisted psychotherapy for PTSD, with insurance funding secured from Medibank. Also operates a clinical trial division and an MDMA analogue discovery program in collaboration with the University of Western Australia.

Drug Pipeline

2

MDMA-assisted psychotherapy

MDMA
Approved
PTSD

TGA-approved in Australia. First commercially delivered MDMA-assisted therapy globally. Medibank private health insurance began covering sessions in June 2025.

MDMA Analogue Library

Pre-clinical

Next-generation MDMA analogues with improved safety profiles, developed in collaboration with the University of Western Australia.

Quick Facts

Type
Public Biotech
Founded
2016
Ticker
ASX: EMD
Lead Stage
Approved
Website
Visit